|
[1] YU X,WANG WJ,JIN JY,et al. Linggui Zhugan decoction combined with probiotics in the treatment of nonalcoholic fatty liver disease[J]. J Changchun Univ Chin Med,2019,35(5):891-894.(in Chinese)喻晓，王雯婕，金嘉悦，等．苓桂术甘汤联合益生菌治疗非酒精性脂肪肝[J]．长春中医药大学学报，2019,35(5):891-894.
|
|
[2] EKSTEDT M,FRANZEN LE,MATHIESEN UL,et al. Longterm follow-up of patients with NAFLD and elevated liver enzymes.[J]. Hepatology,2006,44(4):865-873.
|
|
[3] ARAU'JO AR,ROSSO N,BEDOGNI G,et al. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis:What we need in the future[J]. Liver Int,2018,38(Suppl 1):47-51.
|
|
[4] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology,2016,64(1):73-84.
|
|
[5] LI J. Epidemiology characteristics of nonalcoholic fatty liver disease in Asia[J]. J Clin Hepatol,2018,34(12):34-38.(in Chinese)李婕．亚洲地区非酒精性脂肪性肝病的流行病学特点[J]．临床肝胆病杂志，2018,34(12):34-38.
|
|
[6] MARCHESINI G,BRIZI M,BIANCHI G,et al. Metformin in nonalcoholic steatohepatitis[J]. Lancet,2001,358(9285):893-894.
|
|
[7] LEBEAUPIN C,VALLEE D,HAZARI Y,et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease[J]. J Hepatol,2018,69(4):927-947.
|
|
[8] AKAZAWA Y,NAKAO K. To die or not to die:Death signaling in nonalcoholic fatty liver disease[J]. J Gastroenterol,2018,53(8):893-906.
|
|
[9] SAFARI Z,GERARD P. The links between the gut microbiome and non-alcoholic fatty liver disease(NAFLD)[J]. Cell Mol Life Sci,2019,76(8):1541-1558.
|
|
[10] MUSSO G,CASSADER M,GAMBINO R. Non-alcoholic steatohepatitis:Emerging molecular targets and therapeutic strategies[J]. Nat Rev Drug Discov,2016,15(4):249-274.
|
|
[11] AKIYAMA K,WARABI E,OKADA K,et al. Deletion of both p62 and Nrf2 spontaneously results in the development of nonalcoholic steatohepatitis[J]. Exp Anim,2018,67(2):201-218.
|
|
[12] DAY CP,JAMES OF. Steatohepatitis:A tale of two “hits”?[J]. Gastroenterology,1998,114(4):842-845.
|
|
[13] SCHUSTER S,CABRERA D,ARRESE M,et al. Triggering and resolution of inflammation in NASH[J]. Nat Rev Gastroenterol Hepatol,2018,15(6):349-364.
|
|
[14] BOLAND ML,OLDHAM S,BOLAND BB,et al. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction[J]. World J Gastroenterol,2018,24(16):1748-1765.
|
|
[15] VALENZUELA R,RINCON-CERVERA MA，ECHEVERRA F,et al. Iron-induced pro-oxidant and pro-lipogenic responses in relation to impaired synthesis and accretion of longchain polyunsaturated fatty acids in rat hepatic and extrahepatic tissues[J]. Nutrition,2018,45:49-58.
|
|
[16] JONES RM,NEISH AS. Redox signaling mediated by the gut microbiota[J]. Free Radic Biol Med,2017,105:41-47.
|
|
[17] IPSEN DH,LYKKESFELDT J,TVEDEN-NYBORG P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease[J]. Cel Mol Life Sci,2018,75(18):3313-3327.
|
|
[18] BUZZETTI E,PINZANI M,TSOCHATZIS EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J]. Metab Clin Exp,2016,65(8):1038-1048.
|
|
[19] BELLANTI F,VILLANI R,FACCIORUSSO A,et al. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis[J]. Free Radic Biol Med,2017,111:173-185.
|
|
[20] PFANNER N,WARSCHEID B,WIEDEMANN N. Mitochondrial proteins:From biogenesis to functional networks[J]. Nat Rev Mol Cell Biolm,2019,20(5):267-284.
|
|
[21] LEBEAUPIN C,VALLEE D,HAZARI Y,et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease[J]. J Hepatol,2018,69(4):927-947.
|
|
[22] HENKEL A,GREEN RM. The unfolded protein response in fatty liver disease[J]. Semin Liver Dis,2013,33(4):321-329.
|
|
[23] HAN CY,RHO HYUN S,KIM A,et al. FXR inhibits endoplasmic reticulum stress-induced NLRP3 inflammasome in hepatocytes and ameliorates liver injury[J]. Cell Rep,2018,24(11):2985-2999.
|
|
[24] AROSIO P,ELIA L,POLI MF. Ferritin,cellular iron storage and regulation[J]. IUBMB Life,2017,69(6):414-422.
|
|
[25] DATZ C,MULLER E,AIGNER E. Iron overload and non-alcoholic fatty liver disease[J]. Minerva Endocrinol,2017,42(2):173-183.
|
|
[26] HANDA P,MORGAN-STEVENSON V,MALIKEN BD,et al.Iron overload results in hepatic oxidative stress,immune cell activation,and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice[J]. Am J Physiol Gastrointest Liver Physiol,2016,310(2):g117-g127.
|
|
[27] ATARASHI M,IZAWA T,MIYAGI R,et al. Dietary iron supplementation alters hepatic inflammation in a rat model of nonalcoholic steatohepatitis[J]. Nutrients,2018,10(2):175.
|
|
[28] TAN TC,CRAWFORD DH,JASKOWSKI LA,et al. Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury[J]. Lab Invest,2013,93(12):1295-1312.
|
|
[29] FUKE N,NAGATA N,SUGANUMA H,et al. Regulation of gut microbiota and metabolic endotoxemia with dietary factors[J]. Nutrients,2019,11(10):2277.
|
|
[30] ZHU LX,BAKER RD,ZHU RX,et al. Gut microbiota produce alcohol and contribute to NAFLD[J]. Gut,2016,65(7):1232.
|
|
[31] HU YB,LIU XY,ZHAN W. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis[J]. Drug Des Devel Ther,2018,16(12):2213-2221.
|
|
[32] WANG YX,LI W,CHENG DY,et al. Characteristics of intestinal flora of patients with hepatitis B related decompensated cirrhosis[J/CD]. Chin J Exp Clin Infect Dis(Electronic Version),2019,13(2):110-116.(in Chinese)王艺璇，李炜，程丹颖，等．乙型肝炎失代偿期肝硬化患者肠道菌群特征[J/CD]．中华实验和临床感染病杂志(电子版)，2019,13(2):110-116.
|
|
[33] LI YC,LU Z,RU JH,et al. Saturated fatty acid combined with lipopolysaccharide stimulates a strong inflammatory response in hepatocytes in vivo and in vitro[J]. Am J Physiol Endocrinol Metab,2018,315(1):e745-e757.
|
|
[34] TONELLI C,CHIO IIC,TUVESON DA. Transcriptional regulation by Nrf2[J]. Antioxid Redox Signal,2018,29(17):1727-1745.
|
|
[35] WANG T,ROJO VM,SCHMIDLIN CJ,et al. Kelch-like ECHassociated protein 1(KEAP1)differentially regulates nuclear factor erythroid-2-related factors 1 and 2(NRF1 and NRF2)[J]. J Biol Chem,2018,293(6):2029-2040.
|
|
[36] DINKOVA-KOSTOVA AT,ABRAMOV AY. The emerging role of Nrf2 in mitochondrial function[J]. Free Radic Biol Med,2015,88(Pt B):179-188.
|
|
[37] DU J,ZHANG ML,LU JX,et al. Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK[J]. Endocrine,2016,53(3):701-709.
|
|
[38] SHARMA RS,HARRISON DJ,KISIELEWSKI D,et al. Experimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacologic activation of Nrf2(NF-E2 p45-Related Factor 2)[J]. Cell Mol Gastroenterol Hepatol,2017,5(3):367-398.
|
|
[39] WANG XH,LI CY,XU S,et al. NF-E2-related factor 2 deletion facilitates hepatic fatty acids metabolism disorder induced by high-fat diet via regulating related genes in mice[J].Food Chem Toxicol,2016,(94):186-196.
|
|
[40] YAMADA SJ,KIMURA M,SAITO Y,et al. Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model[J]. J Clin Biochem Nutr,2018,63(2):123-128.
|
|
[41] CHAMBEL SS,SANTOS-GONCALVES A,DUARTE TL. The dual role of Nrf2 in nonalcoholic fatty liver disease:Regulation of antioxidant defenses and hepatic lipid metabolism[J]. Biomed Res Int,2015,(2015):597134.
|
|
[42] ZHANG XX,JI RP,SUN HJ,et al. Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-1α-Nrf2pathway[J]. Free Radic Res,2018,52(2):198-211.
|
|
[43] ZHAO MG,SHENG XP,HUANG YP,et al. Triterpenic acidsenriched fraction from cyclocarya paliurus attenuates non-alcoholic fatty liver disease via improving oxidative stress and mitochondrial dysfunction[J]. Biomed Pharmacother,2018,(104):229-239.
|
|
[44] SHEN BY,ZHAO CX,WANG Y,et al. Aucubin inhibited lipid accumulation and oxidative stress via Nrf2/HO-1 and AMPK signal ing pathways[J]. J Cell Mol Med,2019,23(6):4063-4075.
|
|
[45] GOPAL S,MIKULSKIS A,GOLD R,et al. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies[J]. Mult Scler,2017,23(14):1875-1883.
|
DownLoad: